Abera Bioscience AB (FRA:8WK) Issuance of Debt: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8WK Abera Bioscience AB FRA:8WK
40 GF Score
Price €0.67
! 1 Warning Sign
View Full Analysis

What is Abera Bioscience AB Issuance of Debt?

Abera Bioscience AB FRA:8WK +3.37% 40 Issuance of Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:8WK with a GF Score™ of 40/100. The stock has 1 warning sign investors should review.

Abera Bioscience AB's Issuance of Debt for the three months ended in Jun. 2026 was €0.00 Mil.

Abera Bioscience AB's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil.

Abera Bioscience AB Issuance of Debt Related Terms

Abera Bioscience AB Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Abera Bioscience AB's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abera Bioscience AB Issuance of Debt Chart

Abera Bioscience AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Abera Bioscience AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8WK
40GF Score
Abera Bioscience AB FRA:8WK
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abera Bioscience AB Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €0.00 Mil mean?
Abera Bioscience AB (FRA:8WK) has a Issuance of Debt of €0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Abera Bioscience AB and its competitors.
Is Abera Bioscience AB's Issuance of Debt too high?
Abera Bioscience AB's current Issuance of Debt is €0.00 Mil. Overall, Abera Bioscience AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Abera Bioscience AB's Issuance of Debt compare to VRTX and REGN?
Abera Bioscience AB's Issuance of Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Abera Bioscience AB and its competitors. Abera Bioscience AB's current Issuance of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abera Bioscience AB stock overvalued right now?
Abera Bioscience AB (FRA:8WK) has a current Issuance of Debt of €0.00 Mil. The current Issuance of Debt is €0.00 Mil. Abera Bioscience AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Abera Bioscience AB (FRA:8WK), the current Issuance of Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abera Bioscience AB Business Description

Other Exchanges ABERA:Sweden
Address Box 26029, Uppsala, SWE, 750 26
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.
40GF Score

Get the complete analysis for FRA:8WK

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price